Kenji Fujita

Company: Atsena Therapeutics

Job title: Chief Medical Officer

Seminars:

Updating on Lighthouse Clinical Trial of ATSN-201 to Bring XLRS Patient Closer to Life-Changing Treatment 9:00 am

Presenting the progress of Part B of the Lighthouse study to evaluate the subretinal injection of ATSN-201 Illustrate the nature of AAV.SPR capsids to ensure safe delivery of AAV gene therapy Compare the success and challenges of Part B to Part A of phase II/III to optimize phase II/III trials and beyondRead more

day: Conference Day Two